Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Ocugen Now Has Three Products With ATMP Designation. Two Ocugen products, OCU410 and OCU410ST, received Advanced Therapy Medicinal Product (ATMP) designation from the European Medicines Agency Committee for Advanced Therapies (EMA-CAT). These join OCU400, which received this designation for retinitis pigmentosa (RP) in February 2025. The designation is similar to the Breakthrough Therapy designation from the FDA, allowing increased interactions with the regulators and accelerating regulatory review.
OCU410 Has Completed Phase 2 Dosing In GA. The Phase 2 portion of the ArMaDa (pronounced ‘Armada”) trial has completed enrollment for OCU410 in geographic atrophy (GA), a lesion that results from advancing dry Age-related Macular Degeneration (dry AMD). The study has enrolled 51 patients randomized into a high dose arm, medium dose arm, or control. The completion of the dosing phase was ahead of our expected time frame, keeping the company on schedule to conduct Phase 3 in 2026 and potentially file for regulatory approval in 2028.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients
PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE: ABT) to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the Agreement, Abbott will share insights from recent HeartMate 3™ trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3™ expertise.
“We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrollment efforts,” said Quang X. Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. “Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3™ LVAD, advancing our commitment to bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years.”
Abbott’s HeartMate 3™ LVAD is a mechanical circulatory support device designed for patients with advanced heart failure. Abbott’s heart pumps have set the standard in LVAD therapy. The HeartMate 3™ LVAD is the most advanced LVAD yet and the only one currently available in the United States. According to Business Research Insights, the LVAD market was valued at $1.1 billion in 2023 and is projected to reach $2.4 billion by 2032.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing specialized therapeutics for rare cardiovascular conditions. The Company is developing its late-stage asset, tecarfarin, a new oral vitamin K antagonist (VKA) designed to be a better and safer anticoagulant than warfarin, for individuals with implanted cardiac devices. Although warfarin is widely used off-label for several rare cardiovascular conditions, extensive clinical and real-world data have shown it to have significant serious side effects. With its innovation, Cadrenal aims to meet the unmet needs of this patient population by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges.
Cadrenal is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted left ventricular assist devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).
Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us on LinkedIn.
Safe Harbor
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the collaboration strengthening the potential for improved patient outcomes through improvements in the quality of anticoagulation enhancing hemocompatibility in HeartMate 3™ LVAD patients; Abbott supporting Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs; Abbott sharing insight from recent HeartMate 3™ trials and supporting Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3™ expertise; the support of Abbott further validating the advancement into late-stage clinical development of tecarfarin; bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years; meeting the unmet needs of LVAD patients by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges, Cadrenal building build a pipeline of specialized cardiovascular therapeutics and the LVAD market being projected to reach $2.4 billion by 2032. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to utilize Abbott’s expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal clinical trial for tecarfarin in LVAD patients by Cadrenal and for Cadrenal to provide improved patients outcomes and efficacy and safety for LVAD patients; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, will hold a conference call and live audio webcast on Tuesday, March 18th at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2024. Bitcoin Depot plans to release results before the market open on the same day.
Call Date: Tuesday, March 18, 2025 Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)
Phone Instructions U.S. and Canada (toll-free): 888-596-4144 U.S. (toll): 646-968-2525 Conference ID: 8224936
A replay of the call will be available beginning after 2:00 p.m. Eastern time through March 25, 2025.
U.S. & Canada (toll-free) replay number: 800-770-2030 U.S. toll number: 609-800-9909 Conference ID: 8224936
If you have any difficulty connecting with the conference call, please contact Bitcoin Depot’s investor relations team at 1-949-574-3860.
About Bitcoin Depot Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 48 states and at thousands of name-brand retail locations in 29 states through its BDCheckout product. The Company has the largest market share in North America with over 8,400 kiosk locations as of February 25, 2025. Learn more at www.bitcoindepot.com.
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia
TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized Phase 3 studies
FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia
If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years
CHATHAM, N.J., March 04, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in an oral presentation at the 7th International Congress on Controversies in Fibromyalgia, held March 3-4, 2025, in Vienna, Austria. A copy of the Company’s presentation, titled “Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Treatment of Fibromyalgia at Bedtime to Target Non-Restorative Sleep Showed Durable Pain Reduction in Two Double-Blind Randomized Phase 3 Studies” is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
“Since fibromyalgia is a chronic pain condition, medicines to treat fibromyalgia need to provide durable benefits,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “A randomized controlled study showed that oral, swallowed cyclobenzaprine fails to provide any durable (>1 month) benefit1. In contrast, TNX-102 SL has shown statistically significant, durable activity (3 months) in reducing fibromyalgia pain in two Phase 3 studies. The U.S. Food and Drugs Administration (FDA) has set a PDUFA goal date of August 15, 2025 for a decision on marketing authorization. TNX-102 SL now has the potential to be the first new treatment option for fibromyalgia patients in 15 years.”
Dr. Lederman continued, “TNX-102 SL is designed as a bedtime treatment to target non-restorative sleep, which in turn has shown to result in reduced pain. By providing transmucosal delivery of the tertiary amine tricyclic, TNX-102 SL results in reduced formation of the persistent active metabolite, norcyclobenzaprine (norCBP) relative to oral delivery. NorCBP accumulates after oral delivery and its potent inhibition of the norepinephrine transporter may relate to why oral cyclobenzaprine has transient (one month) activity in fibromyalgia, but not durable (three months) activity in reducing fibromyalgia pain1. Fibromyalgia, has historically been overlooked. Patients’ needs have been inadequately addressed by the three approved products, which results in many patients being prescribed chronic opioids, that are believed to be ineffective, and an actually deleterious, treatment strategy.”
TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a potent antagonist at four post-synaptic receptors, each of which is involved in regulating sleep. TNX-102 SL is designed for rapid, transmucosal absorption and, as demonstrated in pharmacokinetic studies, bypasses first-pass hepatic metabolism resulting in greater bioavailability of cyclobenzaprine that aligns with the sleep cycle to target non-restorative sleep. The sublingual formulation also results in substantially reduced creation of the active metabolite norCyclobenzaprine (norCBP) due to the bypass of first-pass hepatic metabolism. In two 14-week double-blind, randomized, placebo-controlled Phase 3 clinical trials evaluating the safety and efficacy of TNX-102 SL as a bedtime treatment for fibromyalgia, TNX-102 SL 5.6 mg met the pre-specified primary endpoints of significantly reducing daily pain compared to placebo after 14 weeks of treatment. In both trials, TNX-102 SL was generally well tolerated with an adverse event profile comparable to prior studies and with no new safety signals observed.
About Fibromyalgia Fibromyalgia is a common chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system, called central sensitization. Brain imaging studies have localized the functional disorder to the brain’s insula and anterior cingulate cortex. Fibromyalgia afflicts more than 10 million adults in the U.S., the majority of whom are women. Symptoms of fibromyalgia include chronic widespread pain, non-restorative sleep, fatigue, and brain fog (or cognitive dysfunction). Other associated symptoms include mood disturbances, including depression, anxiety, headaches and abdominal pain or cramps. Individuals suffering from fibromyalgia often struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products. Fibromyalgia is now recognized as the prototypic nociplastic syndrome and as a chronic overlapping pain condition (COPC) 2-4. Nociplastic pain is the third primary type of pain in addition to nociceptive pain and neuropathic pain. Many patients present with pain syndromes that are mixtures of the three primary types of pain. Nociplastic syndromes are associated with central and peripheral sensitization. Fibromyalgia can occur without any identifiable precipitating event. However, many fibromyalgia cases follow one or more precipitating event(s) including: post-operative pain, acute or chronic nociceptive or neuropathic pain states; recovery from an infectious illness; a cancer diagnosis or cancer treatment; a metabolic or endocrine stress; or a traumatic event. In the cases of recovery from an infectious illness, fibromyalgia is considered an Infection-Associated Chronic Condition. In addition to fibromyalgia cases associated with other conditions or stressors, the U.S. National Academies of Sciences, Engineering, and Medicine, has concluded that fibromyalgia is a diagnosable condition that can occur after recovery from COVID-19 in the context of Long COVID. Fibromyalgia is also recognized as a Chronic Overlapping Pain Condition, which is a group of related conditions that include chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), irritable bowel syndrome, endometriosis, low back pain, post-concussive syndrome (also known as mild traumatic brain injury), chronic Lyme Disease, chronic diabetic neuropathy and chronic post-herpetic neuralgia.
About TNX-102 SL TNX-102 SL is a centrally acting, non-opioid investigational drug, designed for chronic use. The tablet is a patented sublingual formulation of cyclobenzaprine hydrochloride developed for bedtime dosing for the management of fibromyalgia. Cyclobenzaprine potently binds and acts as an antagonist at four different post-synaptic neuroreceptor subtypes: serotonergic-5-HT2A, adrenergic-α1, histaminergic-H1, and muscarinic-M1-cholinergic receptors. Together, these interactions are believed to target the non-restorative sleep characteristic of fibromyalgia identified by Professor Harvey Moldofsky in 1975. Cyclobenzaprine is not associated with risk of addiction or dependence. The TNX-102 SL tablet is based on a eutectic formulation of cyclobenzaprine HCl and mannitol that provides a stable product which dissolves rapidly and delivers cyclobenzaprine by the transmucosal route efficiently into the bloodstream. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. Patents based on TNX-102 SL’s eutectic composition and its properties have issued in the U.S., E.U., Japan, China and many other jurisdictions around the world and provide market protection into 2034. The European Patent Office’s Opposition Division maintained Tonix’s European Patent EP 2 968 992 in unamended form after an Opposition was filed against it by a Sandoz subsidiary, Hexal AG. Hexal AG did not appeal that decision. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, while reducing the risk of daytime somnolence. Clinical pharmacokinetic studies indicated that relative to oral cyclobenzaprine, TNX-102 SL results in higher levels of exposure during the first 2 hours after dosing and in deceased levels of the long-lived active metabolite, norcyclobenzaprine in both single dose and multiple dose studies, consistent with bypassing first pass hepatic metabolism. At steady state after 20 days of dosing TNX-102 SL, the dynamic peak level of cyclobenzaprine is higher than the background level of norcyclobenzaprine. In contrast, after 20 days of dosing oral cyclobenzaprine, the simulated peak level of cyclobenzaprine is lower than the simulated background level of norcyclobenzaprine.
1Carette S, et al. Arthritis Rheum. 1994, 37(1):32-40. doi: 10.1002/art.1780370106 2Fitzcharles MA, et al. Lancet. 2021;397:2098-110 3Clauw DJ. Ann Rheum Dis. Published Online First: 2024 4Kaplan CM, et al. Nat Rev Neurol. 2024;20, 347–363
Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia, now recognized as the prototypic nociplastic syndrome and as a chronic overlapping pain condition (COPC). TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.
Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.
Important Safety Information
Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:
discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.
Do not use Zembrace or Tosymra if you have:
history of heart problems
narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
uncontrolled high blood pressure
hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
severe liver problems
taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
an allergy to sumatriptan or any of the components of Zembrace or Tosymra
Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.
Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.
Zembrace and Tosymra may cause serious side effects including:
changes in color or sensation in your fingers and toes
sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
hives (itchy bumps); swelling of your tongue, mouth, or throat
seizures even in people who have never had seizures before
The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).
Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.
This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.
You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Office Depot, Inc., together with its subsidiaries, supplies a range of office products and services. It offers merchandise, such as general office supplies, computer supplies, business machines and related supplies, and office furniture through its chain of office supply stores under the Office Depot, Foray, Ativa, Break Escapes, Worklife, and Christopher Lowell brand names. The company also provides graphic design, printing, reproduction, mailing, shipping, and other services through design, print, and ship centers. It has operations throughout North America, Europe, Asia, and Central America. The company also sells its products and services through direct mail catalogs, contract sales force, Internet sites, and retail stores, through a mix of company-owned operations, joint ventures, licensing and franchise agreements, alliances, and other arrangements. As of December 31, 2008, Office Depot operated 1,267 North American retail division office supply stores and 162 international division retail stores, as well as participated under licensing and merchandise arrangements in 98 stores. The company was founded in 1986 and is based in Boca Raton, Florida.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Macro Headwinds. While macro headwinds remain in the B2B and B2C segments, green shoots are appearing, with new B2B contracts and an expanding pipeline of new business opportunities. Over at retail, the Company has seen improved traction with targeted profitable sales campaigns and value added promotions.
Playing to its Strengths. Project “Optimize for Growth” and the B2B focus plays into ODP’s core strengths, such as robust supply chain assets, distribution capabilities, and an expansive B2B customer base. We believe these moves position ODP to unlock sustainable growth and long-term success.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Comtech Telecommunications Corp. engages in the design, development, production, and marketing of products, systems, and services for advanced communications solutions in the United States and internationally. It operates in three segments: Telecommunications Transmission, Mobile Data Communications, and RF Microwave Amplifiers. The Telecommunications Transmission segment provides satellite earth station equipment and systems, over-the-horizon microwave systems, and forward error correction technology, which are used in various commercial and government applications, including backhaul of wireless and cellular traffic, broadcasting (including HDTV), IP-based communications traffic, long distance telephony, and secure defense applications. The Mobile Data Communications segment provides mobile satellite transceivers, and computers and satellite earth station network gateways and associated installation, training, and maintenance services; supplies and operates satellite packet data networks, including arranging and providing satellite capacity; and offers microsatellites and related components. The RF Microwave Amplifiers segment designs, develops, manufactures, and markets satellite earth station traveling wave tube amplifiers (TWTA) and broadband amplifiers. Its amplifiers are used in broadcast and broadband satellite communication; defense applications, such as telecommunications systems and electronic warfare systems; and commercial applications comprising oncology treatment systems, as well as to amplify signals carrying voice, video, or data for air-to-satellite-to-ground communications. The company serves satellite systems integrators, wireless and other communication service providers, broadcasters, defense contractors, military, governments, and oil companies. Comtech markets its products through independent representatives and value-added resellers. The company was founded in 1967 and is headquartered in Melville, New York.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New Capital Infusion. Last night, after the market closed, Comtech Telecommunications announced a new $40 million capital infusion from the current holders of Comtech’s convertible preferred and subordinated debt, or White Hat Capital and Magnetar Financial. The new capital infusion is made on the same terms and conditions as the prior subordinated debt investment.
Uses. Of the $40 million infusion, $27.3 million is being used to prepay the senior secured term loan and $3.2 million to reduce the revolving credit facility, with a waiver of the prepayment penalties that would have been owed in accordance with the terms of the credit agreement.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Key Points: – OPEC+ surprises market with planned April output increase of 138,000 barrels per day – US imposes new tariffs on Canada, Mexico, and China, triggering potential trade tensions – Micro-cap energy stocks face potential volatility and consolidation opportunities
The global oil market is experiencing a pivotal moment that demands close scrutiny from energy sector investors. OPEC+ has recently confirmed a planned April output increase of 138,000 barrels per day, a decision that has immediately rippled through global energy markets. The financial implications are significant: Brent futures dropped 1.45% to $70.58 per barrel, while U.S. West Texas Intermediate (WTI) crude fell 1.07% to $67.64, signaling a complex and potentially challenging investment landscape.
The current market dynamics are further complicated by a series of aggressive trade policies implemented by the U.S. administration. New tariffs of 25% on imports from Canada and Mexico, coupled with increased Chinese import tariffs from 10% to 20%, are creating a multilayered challenge for energy companies across the value chain. These policy shifts are particularly consequential for smaller energy firms that may lack the financial buffers of larger, more established corporations.
For investors focusing on small and micro-cap energy stocks, the current market presents a nuanced investment environment. The compressed profit margins resulting from these market conditions are likely to accelerate sector consolidation. Companies with robust balance sheets, operational efficiency, and strategic adaptability will be best positioned to weather this volatility.
Commodity market experts provide critical insights into these trends. Darren Lim from Phillip Nova emphasizes that the current market is being driven by a combination of OPEC+ output decisions and new tariff implementations. Goldman Sachs analysts offer additional perspective, noting that Russia’s oil flows remain more constrained by production targets than existing sanctions, with potential downside risks to oil price forecasts.
The geopolitical landscape adds another layer of complexity to the investment calculus. President Trump’s recent pause in Ukraine military aid introduces additional uncertainty that could potentially reshape global oil market dynamics and existing sanctions frameworks. This geopolitical tension creates an additional variable for investors to consider when evaluating energy sector investments.
Investors in small and micro-cap energy stocks should focus on several key strategic considerations:
Fundamental Analysis: A deep dive into individual company financials is crucial. Look beyond surface-level metrics to understand each company’s true operational efficiency, debt levels, and ability to adapt to market fluctuations.
Geographical Diversification: Companies with operations across multiple regions may be better positioned to mitigate risks associated with localized economic or political challenges.
Technological Innovation: Energy firms investing in efficient extraction technologies and exploring alternative energy solutions may demonstrate greater long-term resilience.
Cost Management: In a volatile market, companies that can maintain lean operations and control production costs will have a significant competitive advantage.
While the current market presents significant challenges, it simultaneously creates opportunities for strategic investors. The potential for industry consolidation means that well-positioned companies could emerge as attractive acquisition targets or potential market leaders.
Market indicators suggest that volatility in the energy sector is likely to continue. Successful investment strategies will require a disciplined approach, continuous research, and the ability to adapt quickly to changing market conditions.
Investors should maintain a balanced perspective, recognizing that short-term market fluctuations do not necessarily indicate long-term sector performance. Careful analysis, diversification, and a forward-looking investment approach will be key to navigating these complex market dynamics.
Verb Technology Company, Inc. (Nasdaq: VERB) has announced the acquisition of LyveCom, an AI-driven video commerce platform, in a move that positions its MARKET.live platform as one of the most advanced AI-powered social shopping solutions in the industry. The transaction, which is subject to standard conditions including an audit of LyveCom’s financial statements, is expected to close within 60 days. However, Phase 1 of the integration has already been completed, with the newly updated MARKET.live launching today.
The acquisition brings AI-powered technology that enables brands and merchants to deliver an omnichannel livestream shopping experience. This allows businesses to engage customers not just on the MARKET.live platform, but also across their own websites, mobile apps, and social media platforms. With AI-driven video content automation and personalized shopping experiences, the new capabilities streamline content production while expanding reach. LyveCom’s proprietary technology also allows livestreams and shoppable videos to be embedded directly onto merchant websites without affecting site speed. At the same time, content from TikTok, Instagram, and YouTube can be aggregated and repurposed into interactive shopping experiences, enhancing engagement without the need for constant content creation.
The newly enhanced MARKET.live introduces several industry-changing innovations, including one-click simulcasting that allows brands to broadcast live shopping events across multiple platforms such as TikTok Shop, Shopify’s Shop App, and their own e-commerce websites. AI-powered tools will automate video content creation, while frictionless self-serve onboarding makes it easier for millions of Shopify merchants to integrate live and shoppable video in just three clicks. Strategic partnerships with Tapcart, Klaviyo, and Recharge will further expand MARKET.live’s reach in mobile commerce and direct-to-consumer brands. Additionally, an advanced analytics hub will provide real-time insights into shopper behavior, helping merchants refine their strategies and drive conversions.
The acquisition marks a major step toward establishing VERB’s MARKET.live as a leader in livestream and AI-powered social commerce. The platform’s integration with LyveCom’s AI solutions will enhance video content personalization, automate merchandising strategies, and improve conversion rates through AI-powered predictive analytics. The company also plans to launch AI avatar live shopping hosts, which will engage audiences in real time with near-human realism.
According to a report from The Business Research Company, the global social commerce industry is projected to surpass $1.29 trillion by 2028, growing at a CAGR of 13.7%. VERB’s latest move signals its intent to dominate this rapidly expanding space by setting a new standard for AI-powered interactive video commerce. CEO Rory J. Cutaia reinforced the company’s commitment to innovation, stating that the acquisition ensures MARKET.live will bridge brands, marketplaces, and social platforms in a way that enhances engagement and drives sales.
With the integration of LyveCom’s technology, MARKET.live is now positioned as the go-to platform for brands looking to future-proof their business with AI-powered video commerce. As the industry shifts toward interactive shopping experiences, VERB’s strategic expansion underscores its ambition to lead the next evolution of social commerce.
Key Points: – Taiwan Semiconductor Manufacturing Co. (TSMC) plans to invest $100 billion in US chip plants over the next four years. – The investment aligns with efforts to establish the US as a leader in artificial intelligence and semiconductor production. – The announcement follows US tariffs on semiconductor imports and ongoing efforts to reduce reliance on foreign chip manufacturing.
Taiwan Semiconductor Manufacturing Company (TSMC) is preparing to make a historic $100 billion investment in US chip manufacturing, a move expected to bolster America’s position in the global semiconductor race. President Donald Trump is set to formally announce the initiative, which aims to expand domestic production capacity over the next four years.
The investment will fund multiple new semiconductor fabrication plants, reinforcing efforts to establish the United States as a key hub for artificial intelligence and high-performance computing. This move is seen as a major step in reducing US dependence on foreign chip suppliers, particularly amid growing geopolitical tensions that have raised concerns over supply chain vulnerabilities.
TSMC, the world’s largest contract chipmaker, plays a crucial role in supplying semiconductors to major technology firms such as Nvidia and Apple, both of which heavily rely on cutting-edge chips for artificial intelligence applications. The company has already established a presence in the US with its Arizona-based facilities, where it committed an initial $12 billion in 2020. Since then, its investment in the region has swelled to approximately $65 billion, with plans for a third factory already in motion.
The additional $100 billion investment signals a broader commitment to US-based production, which could help mitigate risks associated with global supply chain disruptions. This initiative aligns with the Trump administration’s strategy to strengthen domestic manufacturing and reduce reliance on imports, particularly from Asia.
President Trump has long accused Taiwan of undercutting US chip manufacturing, advocating for tariffs on semiconductor imports as part of his broader trade policy. However, the latest investment from TSMC could help reshape this dynamic by bringing production closer to home, potentially easing tensions while reinforcing economic ties between the US and Taiwan.
Industry experts view this investment as a significant step toward securing US semiconductor supply chains. The recent CHIPS and Science Act, which provides funding to semiconductor companies expanding in the US, has played a role in attracting further investment from industry leaders. In January, TSMC’s Chief Financial Officer, Wendell Huang, expressed confidence that the US government would continue supporting the company’s expansion efforts.
While TSMC’s massive investment will primarily benefit large-scale semiconductor production, smaller cap chip manufacturers may experience mixed effects. On one hand, increased competition from a well-funded industry giant could challenge their market position. However, these companies may also benefit from enhanced supply chain infrastructure, new partnership opportunities, and greater government incentives aimed at bolstering domestic production.
For investors, this development could signal a bullish outlook for the semiconductor sector. Larger players like Nvidia, Intel, and AMD may see increased demand for domestically produced chips, while smaller firms could attract interest based on their role in supporting new manufacturing initiatives. Market analysts will be watching closely to assess which companies stand to gain the most from this significant shift in semiconductor production.
The expansion of US-based semiconductor manufacturing is expected to create thousands of high-skilled jobs while positioning the country as a leader in AI-driven innovation. Analysts believe the move will help stabilize chip supply and reduce costs for American companies reliant on advanced semiconductors.
With formal announcements expected in the coming days, industry stakeholders and policymakers will closely watch how this investment unfolds. The next steps will likely involve site selection, workforce training initiatives, and government incentives to ensure the success of these new facilities.
As TSMC deepens its US footprint, the semiconductor industry braces for a transformative shift that could redefine global supply chains for years to come.
OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced that the Company closed and received the proceeds from the $350 million strategic investment on February 28, 2025. The Company originally announced a binding agreement on the transaction with funds managed by Bain Capital, Morgan Stanley Private Credit, and Newlight Partners on February 10th.
The Company used $260 million of proceeds to pay down its outstanding term loan. The Company now has more than $100 million of available liquidity as it continues to focus on its industry-leading insurance distribution businesses and rapidly expanding healthcare services business.
With the completion of this transaction, SelectQuote also appointed Chris Wolfe of Bain Capital Insurance and Srdjan Vukovic of Newlight Partners to the Board of Directors, each bringing over 20 years of investing and healthcare sector experience to the Company.
Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.
With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.
GROSSE POINTE FARMS, Mich., March 03, 2025 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq: SGA) announced today that it will release its 4th Quarter and Year End 2024 results at 9:00 a.m. EST on Tuesday, March 11, 2025. The company will be holding a conference call on the same date at 11:00 a.m. EST. The dial-in numbers are as follows:
Domestic and International Dial-in Number: (973) 528-0008 Conference Entry Code: 424193
In addition to the Company releasing its 4th Quarter and Year End earnings the Company will discuss:
The Company’s execution of its ongoing digital strategy.
The Company’s ongoing efforts to evaluate non-core asset sales and the use of such proceeds for buybacks, dividends and other corporate purposes.
The Company’s plans to refresh the board.
The Company’s continuing evaluation of market and corporate level expenses to be in line with the Company’s operating verticals.
The Company requests that all parties that have a question that they would like to submit to the Company to please email the inquiry by 10:00 a.m. EST on March 11, 2025, to SagaIR@sagacom.com. The Company will discuss, during the limited period of the conference call, those inquiries it deems of general relevance and interest. Only inquiries made in compliance with the foregoing will be discussed during the call.
Saga’s earnings release will contain certain non-GAAP financial measures including station operating income, trailing 12-month consolidated EBITDA, and same station financial information. A reconciliation of all non-GAAP financial measures to the most directly comparable GAAP measures will be provided in the earnings release.
Saga is a media company whose business is devoted to acquiring, developing, and operating broadcast properties with a growing focus on opportunities complimentary to our core radio business including digital, e-commerce and non-traditional revenue initiatives. Saga owns or operates broadcast properties in 28 markets, including 82 FM and 31 AM radio stations and 79 metro signals. For additional information, contact us at (313) 886-7070 or visit our website at www.sagacom.com.
Key Points: – US manufacturing PMI dipped to 50.3 in February, signaling continued but slowing growth. – Concerns over new tariffs on imports from Canada, Mexico, and China are creating uncertainty for manufacturers. – Prices for raw materials surged to their highest levels since June 2022, potentially impacting production costs.
The US manufacturing sector remained stable in February, though concerns over looming tariffs threatened to disrupt recent gains. While the Institute for Supply Management (ISM) Manufacturing Purchasing Managers’ Index (PMI) registered at 50.3—just above the threshold for expansion—key indicators such as new orders and employment showed signs of weakness.
The report indicated that while the manufacturing industry is maintaining momentum, companies are growing increasingly uneasy about potential tariffs on goods imported from Canada, Mexico, and China. The uncertainty surrounding these trade policies has led to a slowdown in new orders, as customers hesitate to commit to long-term contracts.
Tariffs Fuel Uncertainty and Price Increases Manufacturers reported that trade tensions and prospective retaliatory measures from key US partners were affecting business sentiment. Firms in the chemical and transportation equipment industries, in particular, noted disruptions caused by a lack of clear guidance on tariff implementation. The uncertainty has also impacted investment decisions, with businesses pausing expansion plans.
At the same time, prices for manufacturing inputs surged to their highest levels since June 2022. The ISM’s price index jumped to 62.4 from 54.9 in January, reflecting the growing cost of raw materials. Many manufacturers are concerned that rising costs will eventually be passed on to consumers, potentially reversing recent efforts to stabilize inflation.
Employment and Supply Chain Challenges Employment in the sector contracted after briefly expanding in January. The manufacturing employment index fell to 47.6, suggesting that firms are pulling back on hiring in response to economic uncertainty. With weaker demand and higher costs, companies are taking a cautious approach to workforce expansion.
Supply chains, which had been recovering from disruptions in previous years, also showed signs of strain. The ISM supplier deliveries index increased to 54.5, indicating longer wait times for materials. This is typically a sign of strong demand, but in this case, it reflects supply chain bottlenecks and manufacturers front-loading inventory in anticipation of potential tariff impacts.
Looking Ahead With the Trump administration expected to finalize tariff decisions in the coming days, manufacturers remain on edge. Industries reliant on imported steel, aluminum, and electronic components could face the greatest challenges, particularly as suppliers adjust pricing in response to trade policy changes.
The ISM report follows a series of economic data releases that suggest the US economy may have lost momentum in early 2025. Weak consumer spending, a widening goods trade deficit, and a decline in homebuilding all point to a more cautious economic outlook. Some economists now believe that GDP could contract in the first quarter.
As the manufacturing sector braces for potential headwinds, all eyes remain on the White House’s next moves regarding tariffs. The coming weeks will be critical in determining whether February’s stability can be sustained or if rising costs and trade uncertainty will trigger a broader slowdown.
Mr. Long’s Proven Track Record in Driving E-Commerce Growth and Innovation Includes Leadership Roles at Walmart, Ashley Furniture, and Amazon
Mr. Long will Collaborate with the Existing E-commerce Management Team and Founders to Expand SKYX ‘s Sales and Market Penetration of Its Disruptive Advance and Smart Home Plug & Play Technologies in the U.S. and Canadian Markets
MIAMI, March 03, 2025 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive advanced and smart home platform technology company for homes and buildings, with more than 97 issued and pending patents globally and a portfolio of over 60 lighting and home décor websites, announces today that Huey Long, former Director of Amazon E-Commerce, Senior Vice President of Walmart, and Executive Vice President at Ashley Furniture, has joined SKYX to lead its e-commerce platform.
Mr. Long will work together with the existing e-commerce management team and founders to drive innovation and expand sales and market penetration of SKYX’s advanced and smart home plug & play technologies across the U.S. and Canadian markets.
Long is renowned for his strategic vision and operational excellence across advanced business ecosystems. With over 28 years of experience in e-commerce, omnichannel retail, and global sourcing, he brings a wealth of expertise and leadership to SKYX. His career includes pivotal roles at industry-leading companies, including as Director at Amazon.com, where he spearheaded the development of Amazon Basics, the company’s first private brand initiative. Additionally, he has served as Senior Vice President at Walmart Stores Inc., General Merchandise Manager at Sam’s Club, and Executive Vice President at Ashley Furniture.
Commenting on his appointment, Huey Long said, “I am honored to join SKYX and work with its e-commerce management team and founders at such an exciting time. The company’s commitment to innovation with its game-changing plug & play technologies aligns perfectly with my passion for driving value through innovation, strategic transformation, and operational excellence. I look forward to driving growth and further expanding the market penetration of SKYX’s technologies in the U.S. and Canadian markets. SKYX’s disruptive and smart platform technologies present a unique opportunity for recurring revenues.”
Rani Kohen, Founder/Inventor and Executive Chairman, of SKYX Platforms, said, “Huey’s extensive experience in e-commerce and omnichannel retail makes him uniquely positioned to drive the next phase of growth of our advanced and smart home plug & play platform technologies. We are excited to have Huey on board and look forward to his leadership as we continue to grow our market penetration.”
About SKYX Platforms Corp.
As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 97 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.
Forward-Looking Statements Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.
